USA - NASDAQ:RXRX - US75629V1044 - Common Stock
Overall RXRX gets a fundamental rating of 2 out of 10. We evaluated RXRX against 538 industry peers in the Biotechnology industry. RXRX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RXRX is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -49.84% | ||
ROE | -70.62% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Altman-Z | 0 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.58 | ||
Quick Ratio | 3.58 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.72
+0.09 (+1.94%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 31.72 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.23 | ||
P/tB | 4.96 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -49.84% | ||
ROE | -70.62% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.02 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 17.12% | ||
Cap/Sales | 16.78% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.58 | ||
Quick Ratio | 3.58 | ||
Altman-Z | 0 |